Paper Details

  1. Home
  2. Paper Details

Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.

Author: BurnettAlan K, GibsonBrenda E S, HillsRobert K, HunterAnn E, KjeldsenLars, MilliganDonald, RussellNigel H, WheatleyKeith, YinJohn

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The study found that FLAG-Ida (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin) was an effective remission induction treatment for younger patients with acute myeloid leukemia (AML), resulting in a high complete remission rate after the first course and reduced relapse. Consolidation with MACE/MidAC (amsacrine, cytarabine, etoposide, and then mitoxantrone/cytarabine) was comparable to high-dose cytarabine, with a higher efficacy for high-risk patients. A fifth course of cytarabine was not beneficial.
Paper Details　
Original Abstract of the Article :
PURPOSE: Treatment outcomes in younger patients with acute myeloid leukemia (AML) have improved, but optimization and new combinations are needed. We assess three combinations in induction and consolidation. PATIENTS AND METHODS: Younger untreated patients with AML (median age, 49 years; range, 0 t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.2012.47.4874

データ提供：米国国立医学図書館（NLM）

Optimizing Chemotherapy for Younger Patients with Acute Myeloid Leukemia (AML): The MRC AML15 Trial

This research explores various chemotherapy combinations for younger patients with acute myeloid leukemia (AML). It's like finding the best combination of desert herbs and remedies to combat a deadly disease that threatens the very foundation of a thriving oasis. The study compared different induction and consolidation chemotherapy regimens, analyzing their effectiveness and side effects. The results showed that a combination of fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-Ida) was particularly effective in achieving remission and reducing relapse rates, though it also led to increased myelosuppression. This is like finding a powerful but potentially harsh antidote that can effectively cure a deadly ailment, but requires careful monitoring to avoid negative side effects.

Finding Effective Combinations: A Step Towards Improved AML Treatment

This study provides valuable insights into optimizing chemotherapy regimens for younger AML patients. The FLAG-Ida combination, while presenting some risks, showed significant improvement in remission rates and relapse reduction, paving the way for more personalized and effective treatment strategies. This is like discovering a new source of water in the desert, a resource that can nourish and sustain life.

Staying Informed: The Importance of Medical Expertise

For those diagnosed with AML, this study highlights the importance of seeking expert medical advice to determine the most appropriate treatment plan. This is like finding a seasoned desert guide who can navigate the complex and unpredictable terrain of cancer treatment.

Dr. Camel's Conclusion

This research offers a ray of hope for younger patients diagnosed with AML. By carefully selecting and tailoring chemotherapy regimens, we can significantly improve treatment outcomes and increase the chances of long-term survival. This is like finding a hidden oasis of healing in the vast and unforgiving desert of cancer.

Date :
  1. Date Completed 2014-05-05
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

23940227

DOI: Digital Object Identifier

10.1200/JCO.2012.47.4874

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.